Ipamorelin
[CAS# 170851-70-4]

Identification

• Classification: API >> Circulatory system medication
• Name: Ipamorelin
• Synonyms: (2S)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
• Molecular Formula: C₃₈H₄₉N₉O₅
• Molecular Weight: 711.86
• Protein Sequence: XHXFK
• CAS Registry Number: 170851-70-4
• SMILES: CC(C)(C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCCN)C(=O)N)N

Properties

• Density: 1.3±0.1 g/cm³, Calc.^*
• Index of Refraction: 1.624, Calc.^*
• Boiling Point: 1185.5±65.0 °C (760 mmHg), Calc.^*
• Flash Point: 670.7±34.3 °C, Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Discovery and Applications

Ipamorelin is a synthetic peptide that belongs to a class of compounds known as growth hormone secretagogues (GHS). It was developed in the late 1990s by the pharmaceutical company Novo Nordisk as part of their research into peptides that can stimulate the secretion of growth hormone from the pituitary gland. The discovery of Ipamorelin stemmed from efforts to identify compounds that could mimic the action of ghrelin, a hormone that plays a crucial role in appetite regulation and growth hormone release.

Ipamorelin is structurally similar to ghrelin and acts as a selective agonist for the growth hormone secretagogue receptor (GHSR). It functions by binding to this receptor, which leads to increased levels of growth hormone in the bloodstream. Unlike other GHS, Ipamorelin is unique because it does not significantly affect cortisol or prolactin levels, making it a more selective option for stimulating growth hormone release.

One of the primary applications of Ipamorelin is in the field of endocrinology and anti-aging medicine. It is often used as a therapeutic agent to address growth hormone deficiency in adults and children. By promoting the secretion of growth hormone, Ipamorelin can help improve various physiological functions, including muscle growth, fat metabolism, and overall body composition. This has made it an attractive option for individuals seeking to enhance athletic performance, improve body composition, and counteract age-related decline in growth hormone levels.

In addition to its role in growth hormone deficiency treatment, Ipamorelin has garnered attention in the fitness and bodybuilding communities for its potential to promote muscle growth and fat loss. Athletes and bodybuilders often seek to leverage its effects to optimize training outcomes, enhance recovery, and improve physical performance. However, the use of Ipamorelin in sports is subject to regulations, as it is classified as a prohibited substance by the World Anti-Doping Agency (WADA).

Ipamorelin is typically administered via subcutaneous injection, and its effects can be observed within a short period. The peptide has a relatively short half-life, which necessitates multiple doses throughout the day for sustained effects. Clinical studies have shown that Ipamorelin can lead to significant increases in growth hormone levels without the undesirable side effects associated with some other growth hormone secretagogues.

The safety profile of Ipamorelin is generally favorable, with most users reporting minimal side effects. Commonly reported side effects include mild headaches, flushing, and transient changes in blood glucose levels. However, it is essential for individuals considering the use of Ipamorelin to consult with a healthcare professional to ensure appropriate dosing and monitoring.

Ipamorelin has also been explored for potential applications beyond growth hormone secretion. Research is ongoing to evaluate its role in muscle wasting conditions, metabolic disorders, and other therapeutic areas. As our understanding of growth hormone regulation and its impact on health continues to evolve, Ipamorelin may play a more significant role in clinical practice and therapeutic interventions.

In summary, Ipamorelin is a growth hormone secretagogue that has emerged from the synthesis of peptides aimed at stimulating growth hormone release. Its applications in treating growth hormone deficiency and enhancing physical performance have made it a noteworthy compound in the fields of endocrinology and sports medicine. Ongoing research may further elucidate its potential benefits and expand its therapeutic uses.

References

1998. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5).
DOI: 10.1530/eje.0.1390552

2016. Two ghrelin receptor agonists for adults with malnutrition: a systematic review and meta-analysis. Nutrition Journal, 15(1).
DOI: 10.1186/s12937-016-0214-5

2018. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Testing and Analysis, 11(2).
DOI: 10.1002/dta.2489